{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:55:27Z","timestamp":1792684527948,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.trsl.2020.03.004","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:11:41Z","timestamp":1584367901000},"page":"138-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Vaccines to prevent genital herpes"],"prefix":"10.1016","volume":"220","author":[{"given":"Kevin","family":"Egan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"LaTourette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0765-9460","authenticated-orcid":false,"given":"Harvey M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2020.03.004_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/338231","article-title":"Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis","volume":"185","author":"Wald","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"Aids"},{"key":"10.1016\/j.trsl.2020.03.004_bib0003","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiz203","article-title":"Impact of herpes simplex virus type 2 and human immunodeficiency virus dual infection on female genital tract mucosal immunity and the vaginal microbiome","volume":"220","author":"Keller","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","article-title":"Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data","volume":"4","author":"Looker","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1086\/429299","article-title":"Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines","volume":"191","author":"Schwartz","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0006","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0007","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0008","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.trsl.2020.03.004_bib0009","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0010","article-title":"Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0011","doi-asserted-by":"crossref","first-page":"958","DOI":"10.7326\/0003-4819-98-6-958","article-title":"Genital herpes simplex virus infections: clinical manifestations, course, and complications","volume":"98","author":"Corey","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0012","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJM200003233421203","article-title":"Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons","volume":"342","author":"Wald","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.39409.673657.AE","article-title":"Viral meningitis","volume":"336","author":"Logan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2020.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.trsl.2020.03.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2014.0160","article-title":"Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding","volume":"11","author":"Schiffer","year":"2014","journal-title":"J Royal Soc Interface Royal Soc"},{"key":"10.1016\/j.trsl.2020.03.004_bib0016","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cis891","article-title":"Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women","volume":"56","author":"Bernstein","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ad.2019.06.002","article-title":"Genital infection with herpes simplex virus type 1 and type 2 in Valencia, Spain: a retrospective observational study","volume":"111","author":"Magdaleno-Tapial","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.trsl.2020.03.004_bib0018","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/OLQ.0000000000001076","article-title":"Time trends in first-episode genital herpes simplex virus infections in an urban sexually transmitted disease clinic","volume":"46","author":"Dabestani","year":"2019","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00007435-200302000-00015","article-title":"Natural history of genital herpes simplex virus type 1 infection","volume":"30","author":"Engelberg","year":"2003","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002475","article-title":"Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study","volume":"14","author":"Johnston","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1542\/peds.108.2.230","article-title":"Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections","volume":"108","author":"Kimberlin","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.trsl.2020.03.004_bib0023","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199102143240704","article-title":"Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group","volume":"324","author":"Whitley","year":"1991","journal-title":"N Eng J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0024","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.17.1.1-13.2004","article-title":"Neonatal herpes simplex infection","volume":"17","author":"Kimberlin","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trsl.2020.03.004_bib0026","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199708213370801","article-title":"The acquisition of herpes simplex virus during pregnancy","volume":"337","author":"Brown","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0027","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/jama.289.2.203","article-title":"Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant","volume":"289","author":"Brown","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.trsl.2020.03.004_bib0028","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.semperi.2018.02.004","article-title":"Neonatal herpes simplex virus infections","volume":"42","author":"Pinninti","year":"2018","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1001\/jama.2016.17138","article-title":"Serologic screening for genital herpes: an updated evidence report and systematic review for the US preventive services task force","volume":"316","author":"Feltner","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.trsl.2020.03.004_bib0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2020.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0032","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-122-12-199506150-00001","article-title":"A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]","volume":"122","author":"Langenberg","year":"1995","journal-title":"Ann Int Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/315208","article-title":"Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine","volume":"181","author":"Kohl","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/jvi.41.1.137-144.1982","article-title":"Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein","volume":"41","author":"Para","year":"1982","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0035","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/jvi.65.12.7046-7050.1991","article-title":"Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity","volume":"65","author":"Dubin","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0036","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/JVI.02509-10","article-title":"The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo","volume":"85","author":"Lubinski","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0037","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.4049\/jimmunol.0900722","article-title":"Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons","volume":"184","author":"Posavad","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0038","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine","volume":"210","author":"Awasthi","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0039","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0040","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blind, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus 2 vaccine, HSV529, in adults with or without HSV infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0041","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.79.1.410-418.2005","article-title":"Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs","volume":"79","author":"Hoshino","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","article-title":"A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs","volume":"34","author":"Odegard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virol.2015.10.033","article-title":"Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus","volume":"488","author":"Diaz","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2020.03.004_bib0044","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1128\/JVI.01845-15","article-title":"A herpes simplex virus 2 (HSV-2) gD mutant impaired for neural tropism is superior to an HSV-2 gD subunit vaccine to protect animals from challenge with HSV-2","volume":"90","author":"Wang","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121518","article-title":"Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs","volume":"10","author":"Bernard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0046","doi-asserted-by":"crossref","first-page":"e76407","DOI":"10.1371\/journal.pone.0076407","article-title":"A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice","volume":"8","author":"Dutton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0047","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1128\/JVI.00849-11","volume":"85","author":"Awasthi","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116091","article-title":"Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine","volume":"10","author":"Geltz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0049","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.virol.2017.10.011","article-title":"Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains","volume":"513","author":"Diaz","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2020.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/JVI.06010-11","article-title":"Role of specific innate immune responses in herpes simplex virus infection of the central nervous system","volume":"86","author":"Wang","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0051","doi-asserted-by":"crossref","first-page":"15438","DOI":"10.1073\/pnas.1412767111","article-title":"Direct activation of RIP3\/MLKL-dependent necrosis by herpes simplex virus 1 (HSV-1) protein ICP6 triggers host antiviral defense","volume":"111","author":"Wang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2020.03.004_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145228","article-title":"Antibodies are required for complete vaccine-induced protection against herpes simplex virus 2","volume":"10","author":"Halford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0053","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.1900280","article-title":"IL-36gamma is a key regulator of neutrophil infiltration in the vaginal microenvironment and limits neuroinvasion in genital HSV-2 infection","volume":"203","author":"Gardner","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0054","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/mi.2016.22","article-title":"Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection","volume":"9","author":"Quispe Calla","year":"2016","journal-title":"Mucosal immunology"},{"key":"10.1016\/j.trsl.2020.03.004_bib0055","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.1128\/JVI.77.18.9845-9851.2003","article-title":"Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2","volume":"77","author":"Gillgrass","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0056","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0057","doi-asserted-by":"crossref","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"eLife."},{"key":"10.1016\/j.trsl.2020.03.004_bib0058","doi-asserted-by":"crossref","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0059","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13365-014-0302-2","article-title":"Animal models of herpes simplex virus immunity and pathogenesis","volume":"21","author":"Kollias","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1743-422X-2-67","article-title":"Evidence that spontaneous reactivation of herpes virus does not occur in mice","volume":"2","author":"Gebhardt","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.trsl.2020.03.004_bib0061","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/jvi.66.4.2157-2169.1992","article-title":"Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency","volume":"66","author":"Sawtell","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0062","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/146.3.397","article-title":"Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease","volume":"146","author":"Stanberry","year":"1982","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213401","article-title":"Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: reassessing efficacy using endpoints from clinical trials","volume":"14","author":"Bernstein","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0064","doi-asserted-by":"crossref","first-page":"e02257-16","DOI":"10.1128\/JVI.02257-16","article-title":"Prophylactic herpes simplex virus 2 (HSV-2) vaccines adjuvanted with stable emulsion and toll-like receptor 9 agonist induce a robust HSV-2-specific cell-mediated immune response, protect against symptomatic disease, and reduce the latent viral reservoir","volume":"91","author":"Hensel","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41541-019-0129-1","article-title":"Successful application of prime and pull strategy for a therapeutic HSV vaccine","volume":"4","author":"Bernstein","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.trsl.2020.03.004_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in Rhesus Macaques and highly efficacious in Guinea Pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2020.03.004_bib0067","doi-asserted-by":"crossref","first-page":"e01574-18","DOI":"10.1128\/JVI.01574-18","article-title":"Acute infection and subsequent subclinical reactivation of herpes simplex virus 2 after vaginal inoculation of rhesus macaques","volume":"93","author":"Lo","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0068","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jmp.12293","article-title":"A model of genital herpes simplex virus type 1 infection in Rhesus Macaques","volume":"46","author":"Aravantinou","year":"2017","journal-title":"J Med Primatol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0069","doi-asserted-by":"crossref","first-page":"e8060","DOI":"10.1371\/journal.pone.0008060","article-title":"A macaque model to study vaginal HSV-2\/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy","volume":"4","author":"Crostarosa","year":"2009","journal-title":"PloS one"},{"key":"10.1016\/j.trsl.2020.03.004_bib0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.chom.2018.07.004","article-title":"Species-specific deamidation of cGAS by herpes simplex virus UL37 protein facilitates viral replication","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.trsl.2020.03.004_bib0071","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1128\/jcm.28.1.11-15.1990","article-title":"Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines","volume":"28","author":"Bernstein","year":"1990","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0072","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.virol.2018.10.023","article-title":"Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2","volume":"526","author":"Bourne","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2020.03.004_bib0073","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/infdis\/159.1.89","article-title":"Genital infections due to herpes simplex virus type 2 in male guinea pigs","volume":"159","author":"Stephanopoulos","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0074","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev-immunol-032414-112315","article-title":"Exploiting mucosal immunity for antiviral vaccines","volume":"34","author":"Iwasaki","year":"2016","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0075","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0076","first-page":"754","article-title":"An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, DeltagD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2","volume":"217","author":"Burn","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0077","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/155.1.28","article-title":"Humoral and cell-mediated immunity in neonates with herpes simplex virus infection","volume":"155","author":"Sullender","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0078","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM198701293160503","article-title":"Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections","volume":"316","author":"Prober","year":"1987","journal-title":"N Eng J Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0079","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/infdis\/160.5.770","article-title":"Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection","volume":"160","author":"Kohl","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007095","article-title":"Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs","volume":"14","author":"Hook","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2020.03.004_bib0081","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jri.2007.08.004","article-title":"Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms","volume":"78","author":"Chu","year":"2008","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0082","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.06480-11","article-title":"Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization","volume":"86","author":"Lazear","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006430","article-title":"Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging","volume":"13","author":"Cairns","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2020.03.004_bib0084","doi-asserted-by":"crossref","first-page":"7786","DOI":"10.1128\/JVI.00544-14","article-title":"Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus type 2 glycoprotein D","volume":"88","author":"Whitbeck","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 DeltagD elicits FcgammaR-effector antibodies that protect against clinical isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2020.03.004_bib0086","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/infdis\/jiz521","article-title":"Murine model of maternal immunization demonstrates protective role for antibodies that mediate antibody dependent cellular cytotoxicity in protecting neonates from herpes simplex virus type 1 and type 2","volume":"221","author":"Kao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0087","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes virus fusion and entry: a story with many characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2020.03.004_bib0088","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.283.6.746","article-title":"Immunologic strategies for herpes vaccination","volume":"283","author":"Friedman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2020.03.004_bib0089","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.vaccine.2019.05.068","article-title":"Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants","volume":"37","author":"Awasthi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2020.03.004_bib0091","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/mi.2008.59","article-title":"Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing","volume":"1","author":"Wee","year":"2008","journal-title":"Mucos Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0092","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7007-8-37","article-title":"Immune mechanisms of protection: can adjuvants rise to the challenge?","volume":"8","author":"McKee","year":"2010","journal-title":"BMC Biol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0093","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2020.03.004_bib0094","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mt.2015.138","article-title":"mRNA: fulfilling the promise of gene therapy","volume":"23","author":"Weissman","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2020.03.004_bib0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.trsl.2020.03.004_bib0096","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2020.03.004_bib0097","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0098","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2020.03.004_bib0099","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nature Commun"},{"key":"10.1016\/j.trsl.2020.03.004_bib0100","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2020.03.004_bib0101","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2020.03.004_bib0102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine mediated protection against Zika virus-induced congenital disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2020.03.004_bib0103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2020.03.004_bib0104","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2020.03.004_bib0106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri3803","article-title":"A brief history of T cell help to B cells","volume":"15","author":"Crotty","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2020.03.004_bib0107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Havenar-Daughton","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2020.03.004_bib0108","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1086\/605645","article-title":"Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs","volume":"200","author":"Hoshino","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0109","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1086\/498247","article-title":"Impact of immunization with glycoprotein D2\/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected","volume":"192","author":"Bourne","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0110","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1016\/j.vaccine.2011.06.083","article-title":"Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?","volume":"29","author":"Dasgupta","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0111","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1080\/21645515.2017.1323604","article-title":"A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model","volume":"13","author":"Awasthi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.trsl.2020.03.004_bib0112","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/374002","article-title":"Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs","volume":"187","author":"Bourne","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2020.03.004_bib0113","doi-asserted-by":"crossref","first-page":"e46714","DOI":"10.1371\/journal.pone.0046714","article-title":"Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model","volume":"7","author":"Delagrave","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0115","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2013.10.079","article-title":"Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models","volume":"32","author":"Visalli","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0116","doi-asserted-by":"crossref","first-page":"e17748","DOI":"10.1371\/journal.pone.0017748","article-title":"A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine","volume":"6","author":"Halford","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2020.03.004_bib0117","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1016\/j.vaccine.2012.08.049","article-title":"Inactivated HSV-2 in MPL\/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge","volume":"30","author":"Morello","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0118","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2019.08.077","article-title":"Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2020.03.004_bib0119","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.1500198","article-title":"Immunization with HSV-2 gB-CCL19 fusion constructs protects mice against lethal vaginal challenge","volume":"195","author":"Yan","year":"2015","journal-title":"J Immunol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524420300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:40:16Z","timestamp":1761828016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524420300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":119,"alternative-id":["S1931524420300414"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2020.03.004","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines to prevent genital herpes","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2020.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}